Vanda Pharmaceuticals Urges FDA to Reconsider Slower Drug Review Proposal for FY 2027 Vanda Pharmaceuticals opposes the FDA's FY 2027 proposal that could extend drug review timelines, urging for adherence to the original statutes.

Vanda Pharmaceuticals Urges FDA to Reconsider Slower Drug Review Proposal for FY 2027 #United_States #FDA_Approval #Washington #Vanda_Pharmaceuticals #Drug_Review